0000874015-18-000008.txt : 20180102
0000874015-18-000008.hdr.sgml : 20180102
20180102205035
ACCESSION NUMBER: 0000874015-18-000008
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180101
FILED AS OF DATE: 20180102
DATE AS OF CHANGE: 20180102
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: O'NEIL PATRICK R.
CENTRAL INDEX KEY: 0001564926
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19125
FILM NUMBER: 18503176
MAIL ADDRESS:
STREET 1: C/O ISIS PHARMACEUTICALS, INC.
STREET 2: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000874015
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330336973
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
BUSINESS PHONE: 7609319200
MAIL ADDRESS:
STREET 1: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
FORMER COMPANY:
FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-01-01
0000874015
IONIS PHARMACEUTICALS INC
IONS
0001564926
O'NEIL PATRICK R.
C/O IONIS PHARMACEUTICALS, INC.
2855 GAZELLE COURT
CARLSBAD
CA
92010
0
1
0
0
SVP, Legal & General Counsel
Common Stock
2018-01-01
2018-01-01
5
J
0
53
42.755
A
10486
D
Employee Stock Option (right to buy)
49.25
2018-01-02
2018-01-02
4
A
0
54638
0
A
2019-01-02
2025-01-01
Common Stock
54638
54638
D
Reporting 53 shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2018. These 53 shares may not be sold until July 2, 2018.
Grant of 1/2/2018 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 1/2/2019. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 13,660 shares per year. Following this transaction, the option was exercisable as to 0 on 1/2/2018.
/s/B. Lynne Parshsall, attorney-in-fact
2018-01-02